Targeted therapies consist of anti-tumor angiogenesis, anti-EGFR therapy, tumor immunoregulatory inhibitors, anti-BRAF therapy, and anti-HER-2 therapy [36]. The gene discussed is ERBB2; the disease is neoplasm.